Business Wire

EFFISSIMO-CAPITAL-MGMT

Share
Effissimo Releases Presentation Explaining Proposal to Appoint Independent Investigators at Toshiba

Effissimo Capital Management (“Effissimo”), the largest shareholder of Toshiba Corporation (“Toshiba”) (TYO:6502) through the funds it manages, today released a presentation explaining the reasons behind its proposal for an independent investigation into reported irregularities surrounding Toshiba’s July 2020 Annual General Meeting of Shareholders (“AGM”). Effissimo’s proposal will be voted on by Toshiba’s shareholders at an extraordinary shareholders meeting scheduled for March 18, 2021.

The full proposal in English can be found here .

Supplementing its letter to shareholders dated February 24, 2021, Effissimo’s presentation explains its proposal for an independent investigation into the irregular handling of shareholder voting and shareholder pressure at the closely contested AGM, which Toshiba’s conflicted Audit Committee’s self-audit fails to address.

The presentation provides data showing discrepancies in the claimed delivery times of mailed ballots said by Toshiba’s vote tabulator to have been delivered past the AGM deadline and not counted. It also examines the artificially limited scope and conclusions of Toshiba’s Audit Committee’s investigations into shareholder pressure and vote tampering allegations.

Finally, the presentation provides a detailed historical context of chronic governance and oversight dysfunction at Toshiba that has persisted despite the installation of new management in 2017.

Vote Delivery & Tabulation

  • Inexplicable Delay in Ballot Delivery: Effissimo’s own field tests and review of other Japanese companies’ AGMs confirm Japan Post, in accordance with its own service guidelines, normally takes at most three days to deliver domestic mail. But Toshiba’s vote tabulator insists that it took four days, in breach of Postal Law, for ballots to be delivered.
  • Uncounted Ballots: There are still nearly 1,000—but possibly more than 1,600—additionally reported ballots that have yet to be audited by the Audit Committee due to claims they were delivered too late to be counted. These ballots should have ordinarily arrived prior to the vote deadline, absent the inexplicable delay in ballot delivery.
  • Treatment of Blank Ballots: Mailed ballots made up more than one-third of Toshiba’s quorum at the AGM – a substantial portion of shareholder participation. Roughly 17% of ballots were blank, which Toshiba treated as favorable to management. While lawful, this is clearly an anti-dissident practice that Toshiba could have abandoned after a shareholder proposal in this regard back in 2015.

Shareholder Pressure

  • Decline in Shareholder Participation: In a closely contested vote that attracted intense interest and attention, participation at the AGM declined by three percentage points year-over-year, providing grounds for suspicion that voter suppression in fact occurred.
  • Multiple Institutional Investors Absent from AGM: Credible media outlets have reported that shareholders were “pressured” and/or “threatened” with a probe if they voted against Toshiba management. Toshiba’s voting records indicate that some institutional shareholders that normally vote as a matter of course did not vote at the AGM. Effissimo’s confidential survey confirmed that multiple shareholders were pressured.

Although it may appear complex, the heart of issue is simple. Effissimo believes there should be an independent investigation as opposed to a self-audit by a conflicted Audit Committee.

The Audit Committee, chaired by a director whose reappointment was opposed by more than 40 percent of shareholders at the AGM, is conflicted and is naturally reticent to conduct an uninhibited investigation of possible wrongdoing at the AGM. This conflict manifests itself in the Audit Committee’s reviews and investigations, which we suspect are deliberately limited in scope at the outset to produce a pre-determined result.

The right to vote is what is at stake. Shareholders must not passively accept the Board’s explanations at face value and allow the status quo of weak governance to persist. Failure to perform a thorough and independent investigation will set a harmful precedent not only for Toshiba but also for corporate Japan as a whole.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye